Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Shan, Xiu ^a   Fu, Yuan Shan ^a   Aziz, Faisal ^a   Wang, Xiao Qi ^b   Yan, Qiu ^a   Liu, Ji Wei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; ENTINOSTAT; GINSENOSIDE RG 3; HISTONE DEACETYLASE 3; LYSINE; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; GINSENOSIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG STRUCTURE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LYMPH NODE METASTASIS; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN ACETYLATION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ACETYLATION; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

PANAX GINSENG;

ACETYLATION; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GINSENOSIDES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MELANOMA; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919492823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115401     Document Type: Article

References (49)

1. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27: 3-9.
2. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-185.
3. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, et al. (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22: 1118-1125.
4. Menzies AM, Lon GV (2013) Recent advances in melanoma systemic therapy, BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 49: 3229-3241.
5. Ma C, Armstrong AW (2014) Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat 25: 401-408.
6. Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25.
7. Li DW, Sun XD, Zhang LL, Yan B, Xie SB, et al. (2014) Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulatethe motility of pancreatic cancer cells. Protein Cell 5: 214-223.
8. Zhang ZH, Yamashita H, Toyama T, Sugiura H, Omoto Y, et al. (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10: 6962-6968.
9. Huang BH, Laban M, Leung CH, Lee L, Lee CK, et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404.
10. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, et al. (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268.
11. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, et al. (2009) Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15: 91-99.
12. Bartling B, Hofmann HS, Boettger T, Hansen G, Burdach S, et al. (2005) Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 49: 145-154.
13. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548-13558.
14. Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer lett 280: 168-176.
15. Brooks CL, Gu W (2011) The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2: 456-462.
16. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, et al. (2000) Histone deacetylases specifically downregulate p53-dependent gene activation. J Biol Chem 275: 20436-20443.
17. Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, et al. (2013) Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia 3: 680-689.
18. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, et al. (2010) Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumor Biol 31: 533-539.
19. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
20. Molife LR, Bono JS (2011) Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs 20: 1723-1732.
21. McDermott J, Jimeno A (2014) Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barc) 50: 337-345.
22. Diyabalanage HVK, Granda ML, Hooker JM (2013) Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett 329: 1-8.
23. Lee JY, Jung KH, Morgan MJ, Kang YR, Lee HS, et al. (2013) Sensitization of TRAIL-induced cell death by 20(S)-Ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther 12: 274-285.
24. Park EH, Kim YJ, Yamabe N, Park SH, Kim HK, et al. (2014) Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res 38: 22-27.
25. Pan XY, Guo H, Han J, Hao F, An Y, et al. (2012) Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. European J Pharmacol 683: 27-34.
26. Sun Y, Lin HS, Zhu YZ, Feng JF, Chen ZT, et al. (2006) A randomized, prospective, muti-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients. CJLC 9: 254-258.
27. Liu JW, Sun P, Yan Q, Paller AS, Wang XQ, et al. (2009) De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res 69: 8662-8669.
28. Laura M, Alwan LM, Grossmann K, Daniel Sageser D, Atta JV, et al. (2014) Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Targ Oncol 9: 63-71.
29. Sibaud V, Lamant L, Maisongrosse V, Delord JP (2013) Adverse skin reactions induced by BRAF inhibitors: A systematic review. Ann Dermatol Venereol 140: 510-520.
30. Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS (2009) Inhibition of NF-κB by Ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 32: 755-765.
31. Lee CK, Park KK, Chung AS, Chung WY (2012) Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol 50: 2565-2574.
32. Yoo JH, Kwon HC, Kim YJ, Park JH, Yang HO, et al. (2010) KG-135, enriched with selected ginsenosides, inhibits the proliferation of human prostate cancer cells in culture and inhibits xenograft growth in athymic mice. Cancer Lett 289: 99-110.
33. Liu TG, Huang Y, Cui DD, Huang XB, Mao SH (2009) Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 9: 250-251.
34. Oie S, Matsuzaki K, Yokoyama W, Murayama A, Yanagisawa J (2013) HDAC3 regulates stability of estrogen receptor a mRNA. Biochem Biophys Res Commun 432: 236-241.
35. Chen CQ, Chen CS, Chen JJ, Zhou LP, Xu HL, et al. (2013) Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol Cell Biochem 383: 137-148.
36. Du ZW, Song J, Wang Y, Zhao Y, Wang Z, et al. (2010) DNMT1 Stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci signal 3: ra80.
37. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Pili R, et al. (2012) Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 7: e30815.
38. Bode AM, Dong ZG (2004) Post-translational modification of p53 in tumorigenesis. Nature 4: 793-805.
39. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609-622.
40. Thakur VS, Gupta K, Gupta S (2012) Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 41: 353-361.
41. Waf1/Cip1. Mol Cell Biol 26: 2782-2790.
42. Li MY, Luo JY, Brooks CL, Gu W (2002) Acetylation of p53 inhibits its ubiquitination by mdm2. J Biol Chem 277: 50607-50611.
43. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, et al. (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20: 1331-1340.
44. Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, et al. (2012) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 106: 116-25.
45. Jazirehi AR, Arle D (2013) Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol 2: 55-74.
46. Lai F, Guo ST, Jin L, Jiang CC, Wang CY, et al. (2013) Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis 4: e655.
47. Yamamoto SJ, Yamano T, Tanaka M, Hoon DSB, Takao S, et al. (2003) A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther 10: 179-186.
48. Boissinot M, Inman M, Hempshallb A, James SR, Gillc JH, et al. (2012) Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. Leuk Res 36: 1304-1310.
49. Feng LF, Pan M, Sun J, Lu HQ, Shen Q, et al. (2012) Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med 91: 49-58.